Inovio up 1% on encouraging INO-3106 results
Apr. 03, 2019 9:46 AM ETInovio Pharmaceuticals, Inc. (INO)By: Douglas W. House, SA News Editor7 Comments
- Inovio Pharmaceuticals (NASDAQ:INO +1.4%) is up on light volume in early trade on the heels of results from a pilot study of INO-3106 in two patients with recurrent respiratory papillomatosis, a rare HPV-associated disease characterized by persistent noncancerous tumor growths in the airways. The data were presented at AACR in Atlanta.
- Surgery to remove the growths, usually multiple times each year, is the only current treatment.
- Following their last dose of INO-3106, a non-invasive immunotherapy, both patients have been surgery-free, one for two years and the other for one year.
- Development is ongoing.